



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO		
09/943,443	08.	/30/2001	Jean-Christophe Audonnet	454313-2220.1	9956	
20999	7590	01/18/2006		EXAMINER		
		NCE & HAUG	CHEN, STACY BROWN			
	FTH AVENUE- 10TH FL. YORK, NY 10151			ART UNIT	PAPER NUMBER	
				1648		
				DATE MAILED: 01/18/2006		
				, the second sec		

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)
09/943,443	AUDONNET ET AL.
Examiner	Art Unit
Stacy B. Chen	1648

Before the Filing of an Appeal Brief	Examiner	Art Unit	
	Stacy B. Chen	1648	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress
THE REPLY FILED 27 December 2005 FAILS TO PLACE THIS	S APPLICATION IN CONDITION FO	OR ALLOWANCE.	
 The reply was filed after a final rejection, but prior to or on this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a Nova Request for Continued Examination (RCE) in compliance time periods: a) The period for reply expires 6 months from the mailing date 	wing replies: (1) an amendment, affortice of Appeal (with appeal fee) in one with 37 CFR 1.114. The reply must of the final rejection.	idavit, or other evider compliance with 37 Cl ust be filed within one	nce, which FR 41.31; or (3) of the following
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Is Examiner Note: If box 1 is checked, check either box (a) or	ater than SIX MONTHS from the mailing	g date of the final rejecti	on.
TWO MONTHS OF THE FINAL REJECTION. See MPEP 7	06.07(f).		
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of ex under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the corresponding amount shortened statutory period for reply original replayment than three months after the mailing date.	of the fee. The approprinally set in the final Offite te of the final rejection, o	iate extension fee ce action; or (2) as even if timely filed,
2. The Notice of Appeal was filed on <u>27 December 2005</u> . A of the date of filing the Notice of Appeal (37 CFR 41.37(a appeal. Since a Notice of Appeal has been filed, any reply <u>AMENDMENTS</u>)), or any extension thereof (37 CFI	R 41.37(e)), to avoid	dismissal of the
 3. The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co (b) They raise the issue of new matter (see NOTE belo (c) They are not deemed to place the application in befappeal; and/or 	nsideration and/or search (see NO w); tter form for appeal by materially re	TE below); ducing or simplifying	
(d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).		ected claims.	
4. The amendments are not in compliance with 37 CFR 1.1.		mpliant Amendment	(PTOL-324).
5. Applicant's reply has overcome the following rejection(s)6. Newly proposed or amended claim(s) would be al non-allowable claim(s).		timely filed amendme	ent canceling the
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is protected. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 21-25. Claim(s) withdrawn from consideration: 11-20.	· · · · · · · · · · · · · · · · · · ·	II be entered and an e	explanation of
AFFIDAVIT OR OTHER EVIDENCE			
8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e).			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to of showing a good and sufficient reasons why it is necessary	overcome <u>all</u> rejections under appea	al and/or appellant fai	ils to provide a
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	ntry is below or attach	ied.
11. The request for reconsideration has been considered by See Continuation Sheet.			nce because:
12. Note the attached Information Disclosure Statement(s). 13. Other:	(PTO/SB/08 or PTO-1449) Paper N	lo(s)	

Continuation Sheet (PTO-303)

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's arguments rebutting the rejections of record are acknowledged and have been carefully considered. The arguments are primarily drawn to the following:

Applicant distinguishes the instant invention from that of Wardley by arguing that the instant plasmid is adminstered without incorporation into a vector. Whereas Wardley uses a vector to deliver the plasmid. Applicant points to page 4, lines 14-17 and Example 20 of the instant specification for support of this argument. Applicant argues that Mazzara fails to remedy the deficiencies of Wardley because Mazzara makes use of viral vectors. In response to Applicant's argument, the specification and Example 20 discloses an embodiment of naked plasmids. However, the claim language still does not reflect this concept.

Applicant also argues that the claims specifically require that the administered plasmid express the nucleic acid in vivo in a feline host cell. Applicant argues that Wardley fails to teach the in vivo expression aspect of the instantly claimed invention. Wardley teaches DNA expressed in an expression system, not in vivo in a feline host cell. In response to this argument, the nucleic acid of Wardley is expressed in vivo via the viral vector. Though Applicant intends for the plasmids to be administered and expressed without a viral vector, Wardley's viral vectors deliver and express nucleic acid, thus reading on the claimed invention.

During the telephone conversation between the examiner and Angela Collison on December 20, 2005, possible amendments were discussed to overcome the art rejections. It is understood that the claims are intended to be limited to naked plasmids, however, the claims language still reads on and encompasses vectors. Therefore, the rejection of claims 21, 24 and 25 under 35 U.S.C. 102(a) as being anticipated by Wardley et al. (WO95/30019, "Wardley") is maintained for reasons of record, as is the rejection of claims 22, 23 and 25 under 35 U.S.C. 103(a) as being unpatentable over Wardley as applied to claims 21, 24 and 25 above, and further in view of Mazzara et al. (U.S. Patent 5,804,196, "Mazzara").

Stacy B. Chen January 13, 2006

Stay B Cha